Develops targeted cancer medicines for patients selected by cancer-related genetic changes, including medicines for solid tumors and brain cancers.
10-K for FY2025, filed Mar 5, 2026
Revenue has come mainly from Gilead license and collaboration agreements. Tango receives fees for licenses and research and development services; license fees may be paid upfront, while research fees are earned as the work progresses.
10-K for FY2025, filed Mar 5, 2026The Company’s revenues were primarily generated through its license and collaboration agreements with Gilead. Refer to Note 3…View ↗
Exclusive License Rights — If the license to the Company’s intellectual property is determined to be distinct from the other promises or…View ↗
Research and Development Services — The obligations under the Company’s collaboration agreements may include research and development…View ↗
$62.4M
10-K for FY2025, filed Mar 5, 2026
$62.4M ↗No. It lost $101.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$68.4MView ↗
8-K, filed Nov 9, 2026
PIVOTAL STUDY PLANS. Based upon the encouraging Phase 1/2 data and discussions with the US Food and Drug Administration (FDA), Tango…View ↗
8-K, filed Oct 23, 2026
As of the data cutoff date of August 20, 2026, updated data from the ongoing Phase 1/2 study demonstrated an 82% objective response rate…View ↗
Growing. Revenue grew 68% in 4 years, from $37M in FY2021 to $62.4M in FY2025, about 14% a year.
Competes with AstraZeneca, Amgen, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Merck KGaA, Pfizer, Lilly, Roche, Artios Pharma, BeOne, Exelixis, IDEAYA Biosciences, Repare Therapeutics, Servier Pharmaceuticals, Abbisko, Insilico Medicine, and Jubilant Therapeutics
10-K for FY2025, filed Mar 5, 2026We face direct competition from pharmaceutical and biotechnology companies leveraging the principle of synthetic lethality as well as…View ↗
Loading...